PROD: Prospective Randomized Controlled Trial of Obstructed Defecation Surgery

Sponsor
NorthShore University HealthSystem (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05747027
Collaborator
Weill Medical College of Cornell University (Other)
115
2
60

Study Details

Study Description

Brief Summary

Obstructive defecatory syndrome (ODS) or inability to completely empty bowel is characterized by a combination of straining, incomplete evacuation, and the use of digital manipulation with bowel movement. This is a common condition with estimated incidence of 15-20% in the adult female population.

Laparoscopic abdominal ventral rectopexy is an established surgical technique aimed at restoring rectal support in women with this condition. It is the most common surgery used nowadays to treat ODS. Transvaginal sacrospinous rectopexy, is an innovative procedure which has been shown to be safe and effective in the treatment of stool entrapment. Currently it is unknown whether one of the procedures mentioned is superior to the other regarding surgical outcomes and patient experience. The purpose of this research is to compare the outcomes of these two procedures considering their efficacy to improve symptoms.

During the study, participants will be randomized to undergo one of two procedures for treatment of inability to completely empty their bowel and/or rectal prolapse: 1) laparoscopic abdominal ventral rectopexy; 2) transvaginal sacrospinous rectopexy. Following the procedure, participants will be asked to return to the office for a follow-up visit 2-weeks, 3-, 12- and 24-months after the surgery. During each follow-up visit participants will undergo symptom evaluation, pelvic exam and transvaginal pelvic ultrasound to evaluate surgical success.

Condition or Disease Intervention/Treatment Phase
  • Procedure: laparoscopic abdominal ventral rectopexy
  • Procedure: Transvaginal sacrospinous rectopexy
  • Diagnostic Test: MR Defecography
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
115 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Masking Description:
The study surgeon is providing clinical care to enrolled subjects, thus masking the surgeon to treatment allocation or subject symptoms is not practical or feasible, other than the allocation concealment prior to surgical randomization (treatment allocation in sequentially numbered, sealed, opaque envelopes). It is our intent that when feasible and ethical, all assessors and the subject will be masked to the treatment allocation.
Primary Purpose:
Treatment
Official Title:
Prospective Randomized Controlled Trial of Obstructed Defecation Surgery: Comparing Transvaginal Rectopexy, Ventral Mesh Rectopexy, and POP Repair
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2026
Anticipated Study Completion Date :
Mar 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: laparoscopic abdominal ventral rectopexy

Procedure: laparoscopic abdominal ventral rectopexy
Laparoscopic abdominal ventral rectopexy is an established surgical technique used to restore rectal support in women with obstructive defecatory syndrome (ODS). It is the most common surgery used to treat ODS.

Diagnostic Test: MR Defecography
MR imaging will be in the supine position with hips and knees bent at 45°using a closed-configuration 1.5T magnet (Siemens, Magnetom Avanto) and a Synergy body phased-array coil. Intravenous contrast will not be used. Three anatomic measurements relating to rectal support will be recorded at rest, and then also at the moment of maximum evacuation.

Experimental: transvaginal sacrospinous rectopexy

Procedure: Transvaginal sacrospinous rectopexy
Transvaginal sacrospinous rectopexy is an innovative procedure which has shown to be safe and effective in the treatment of stool entrapment.

Diagnostic Test: MR Defecography
MR imaging will be in the supine position with hips and knees bent at 45°using a closed-configuration 1.5T magnet (Siemens, Magnetom Avanto) and a Synergy body phased-array coil. Intravenous contrast will not be used. Three anatomic measurements relating to rectal support will be recorded at rest, and then also at the moment of maximum evacuation.

Outcome Measures

Primary Outcome Measures

  1. Degree of rectal hypermobility preoperatively [preoperatively]

    The degree of rectal hypermobility measured via ultrasound (i.e. compression ratio).

  2. Degree of rectal hypermobility 2 months post-operatively [2 months post-operatively]

    The degree of rectal hypermobility measured via ultrasound (i.e. compression ratio) preoperatively.

  3. Degree of rectal hypermobility 12 months post-operatively [12 months post-operatively]

    The degree of rectal hypermobility measured via ultrasound (i.e. compression ratio) preoperatively.

  4. Degree of rectal hypermobility 24 months post-operatively [12 months post-operatively]

    The degree of rectal hypermobility measured via ultrasound (i.e. compression ratio) preoperatively.

  5. POPQ assessment preoperatively [preoperatively]

    The assessment of the degree of prolapse of pelvic organs.

  6. POPQ assessment 2 months post-operatively [2 months post-operatively]

    The assessment of the degree of prolapse of pelvic organs.

  7. POPQ assessment 12 months post-operatively [12 months post-operatively]

    The assessment of the degree of prolapse of pelvic organs.

  8. POPQ assessment 24 months post-operatively [24 months post-operatively]

    The assessment of the degree of prolapse of pelvic organs.

  9. PFDI preoperatively [preoperatively]

    A validated, condition-specific instrument that assesses pelvic symptoms and the associated degree of bother.

  10. PFDI 2 months post-operatively [2 months post-operatively]

    A validated, condition-specific instrument that assesses pelvic symptoms and the associated degree of bother.

  11. PFDI 12 months post-operatively [12 months post-operatively]

    A validated, condition-specific instrument that assesses pelvic symptoms and the associated degree of bother.

  12. PFDI 24 months post-operatively [24 months post-operatively]

    A validated, condition-specific instrument that assesses pelvic symptoms and the associated degree of bother.

Secondary Outcome Measures

  1. Postoperative pain by pain scale [preoperatively, and then at 2 weeks and 2, 12, and 24 months postoperatively]

    Subjects will complete the Pain Scale. The pain will be measured on a scale of no pain, mild pain, moderate pain, severe pain, very severe pain, or worst possible pain. No pain will indicate the best outcome whereas the worst possible pain will indicate the worst outcome.

  2. Postoperative pain by an assessment of pain medication use [preoperatively, and then at 2 weeks and 2, 12, and 24 months postoperatively]

    Subjects will complete an assessment of pain medication use.

  3. Postoperative functional activity level [preoperatively, and then at 2 weeks and 2, 12, and 24 months postoperatively]

    Subjects will complete the Activity Assessment Scale which measures functional activity. The activity level will be measured on a scale of no activity, moderate activity, and full activity. Full activity will indicate the best outcome whereas no activity will indicate the worst outcome.

  4. Global improvement in bladder function [2, 12, and 24 months postoperatively]

    Subjects will complete the Patient Global Impression of Improvement

  5. Pelvic Organ Prolapse Distress Inventory (POPDI) [2 and 24 months postoperatively]

    Prolapse symptoms assessed by POPDI. The symptoms will be measured on a scale of 0, not present, to 4, quite a bit.

  6. Colorectal-Anal Distress Inventory (CRADI) [2 and 24 months postoperatively]

    Colorectal symptoms assessed by CRADI. The symptoms will be measured on a scale of 0, not present, to 4, quite a bit.

  7. Urinary Distress Inventory (UDI) [2 and 24 months postoperatively]

    Urinary symptoms assessed by UDI. The symptoms will be measured on a scale of 0, not present, to 4, quite a bit.

  8. Pelvic floor Impact Questionnaire (PFIQ) [2 and 24 months postoperatively]

    Quality of life measured by PFIQ.

  9. Short Form 36 Health Survey Questionnaire (SF-36) [2 weeks, 2 and 24 months postoperatively]

    Quality of life measured by SF-36.

  10. EuroQol-5D (EQ-5D) [2 and 24 months postoperatively]

    Quality of life measured by EQ-5D.

  11. Pelvic floor muscle strength [2 and 24 months postoperatively]

    Pelvic floor muscle strength will be measured by the Brink Scale in which the ratings are for a composite score of 3-12 added. A higher score means better muscle function.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. OD symptoms as indicated by an affirmative response to either questions 7, 8 or 14 of the Pelvic Floor Distress Inventory (PFDI):

  2. Do you feel you need to strain too hard to have a bowel movement?

  3. Do you feel you have not completely emptied your bowels at the end of a bowel movement?

  4. Does part of your bowel ever pass through the rectum and bulge outside during or after a bowel movement?

  5. Rectal hypermobility defined as a compression ratio greater than 50% according to ultrasound

  6. Patient planning on undergoing surgery for the repair of pelvic organ prolapse

  7. Available for 24-months of follow-up

  8. Able to complete study assessments, per clinician judgment

  9. Able and willing to provide written informed consent

Exclusion Criteria:
  1. Contraindication to abdominal and transvaginal rectopexy in the opinion of the treating surgeon

  2. History of previous surgery that included any type of surgery for rectal prolapse

  3. Pelvic pain or dyspareunia due to levator ani spasm that would preclude a PMT program

  4. Previous adverse reaction to synthetic mesh

  5. Current cytotoxic chemotherapy or current or history of pelvic radiation therapy

  6. History of two inpatient hospitalizations for medical comorbidities in the previous 12 months

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • NorthShore University HealthSystem
  • Weill Medical College of Cornell University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ghazaleh Rostami Nia, Director of Research Division of Urogynecology, NorthShore University HealthSystem, NorthShore University HealthSystem
ClinicalTrials.gov Identifier:
NCT05747027
Other Study ID Numbers:
  • EH22-284
First Posted:
Feb 28, 2023
Last Update Posted:
Feb 28, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 28, 2023